Cure My Disease

Don't miss your cure!

 Log in / Sign up

Food vs. fasting: new study tests best way to take cancer pill

NCT ID NCT06075277

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study in 16 healthy men tested whether taking the cancer drug zongertinib with a high-fat meal changes how much of the drug gets into the blood. Each participant took one dose on an empty stomach and another after a fatty meal, so researchers could compare. The results will help doctors give clear instructions on whether to take this drug with or without food.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zongertinib (also called BI 1810631)
What this could lead to
If successful, this study will show whether zongertinib should be taken with or without food, helping future patients get the right dose.
What could go wrong
This is a very early, small study in healthy people, not patients. It only looks at drug levels in the blood, not whether the drug works for cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • CRS Clinical Research Services Berlin GmbH

    Berlin, 13627, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.